CytoMed Therapeutics Ltd (NASDAQ: GDTC) - A Rising Star in Singapore's Cancer Biotechnology Sector

In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company's technological approach, clinical trial progress, global strategic expansion - particularly in China and India - financing status, and deep insights into the global biotechnology industry.

Image: https://www.wdwire.com/wp-content/uploads/2026/07/image-5.png

1. Company Overview & Core Technology

Company Background

CytoMed is a clinical-stage biotech spin-off from ASTAR, Singapore's national scientific research agency. The company focuses on developing affordable cancer therapy using patented allogeneic Gamma Delta T Cells derived from healthy donors.

Mission

The company aims to address the major limitations of existing cell therapies such as CAR-T, including high treatment costs and lengthy manufacturing timelines. By using blood from healthy donors to manufacture "off-the-shelf" immune cells, the company aims to reduce production costs and enable global distribution.

Technological Advantages

Safety

Gamma Delta T Cells have a lower risk of causing Graft-versus-Host Disease (GVHD), making them suitable for allogeneic transplantation.

Versatility

The cells express CARs (Chimeric Antigen Receptors) targeting NKG2D ligands, enabling recognition of multiple cancer types that express stress-related molecules, including Solid tumors & Hematological malignancies.

2. Clinical Trial Progress

Singapore ANGELICA Trial

Nature of the Trial

Ongoing first-in-human clinical trial targeting patients with:

* Advanced solid tumors
* Hematological malignancies

Progress

The trial comprised 12 patients in total, and treatment has been completed for half of the participants (6 patients).

Objective

To complete the Phase 1 clinical trial and evaluate before embarking on Phase 2 by next year 2027:

* Safety
* Efficacy of the CAR-modified version

Malaysia Clinical Trial

Strategy

CytoMed plans to launch a first-in-human clinical trial for the unmodified version of the therapy, which is expected to be significantly less expensive than the CAR-T version.

Collaboration

The company is collaborating with Universiti Malaya Hospital and is preparing to submit trial documentation to regulators and start by this year 2026.

3. Strategic Expansion & Acquisitions

Acquisition of TC BioPharm (UK)

Through this acquisition, CytoMed obtained feeder-free manufacturing technology, solving logistical challenges associated with cross-border transportation of specialized feeder cells and strengthening its cancer therapy platform.

Acquisition of Longevity Bank (Malaysia)

Background

In mid-2024, CytoMed acquired a Malaysian cord blood bank that had entered liquidation due to the impact of the pandemic. The bank had approximately 12,000 customers.

Strategic Purpose

The acquisition provides access to cord blood resources for the development of Natural Killer (NK) Cell therapies from pristine cord blood.

NK cells have potential applications in:

* Anti-aging
* Elimination of senescent cells

This acquisition also broadens the company's therapeutic pipeline.

4. Global Market Strategy: Focus on China & India

China (Key Strategic Focus)

Policy Opportunity

CytoMed is closely monitoring China's "Directive 818," which allows hospitals conducting investigator-initiated trials (IITs) to charge patients, thereby helping subsidize biotechnology companies' R&D and manufacturing costs.

Competitive Advantage

Compared with the capital-intensive "cash-burning" model commonly seen in Western biotech companies, the Chinese model is viewed as more sustainable.

China's Government-backed biotech parks, Pragmatic regulatory policies & Strong venture capital ecosystem have made the country highly attractive for biotechnology development.

Market Potential

China has a massive cancer patient population and regulatory flexibility for compassionate-use style commercialization making it a critical strategic market for CytoMed.

India

As one of the world's two largest population centres, India is also a major target market for the company.

United States

Although CytoMed collaborates with MD Anderson Cancer Center - where animal studies showed effectiveness against AML - the company currently does not prioritize the U.S. market due to the long time and extremely high cost of clinical trials.

5. Financial Position & Industry Perspectives

Financial Status

* The company raised only USD 8 million during its 2023 IPO due to difficult biotech market conditions at the time.
* However, management has maintained disciplined spending while seeking partners to co-develop its proprietary allogeneic cancer technologies.

View on the "Biotech Winter"

The Chairman believes the biotech industry is currently experiencing a "winter" caused by:

* Excessively high valuations during the pandemic era
* SPAC-related speculation
* Significant investor losses
* Tightening capital markets

The company also faces:

* Heavy short-selling pressure
* Interference from day traders

Strategic Pivot

To survive the difficult funding environment, CytoMed is shifting toward closer collaboration with hospitals to provide treatments for "no-option" patients.

The company benefits from low cost infrastructure in Southeast Asia and aims to:

* Attract international medical tourists
* Leverage Malaysia's "Medical Tourism Year 2026"
* Generate revenue while simultaneously collecting clinical data

6. Regulatory Advocacy

Compassionate Use

CytoMed advocates for regulators to adopt a more flexible approach for terminal patients who have exhausted all available treatment options, allowing access to new cell therapies.

East-West Differences

The Chairman noted that Eastern societies, particularly in Southeast Asia, generally have less aggressive litigation cultures compared with Western countries such as the United States.

This creates a more favourable environment for Compassionate Use programs, allowing terminal patients to try innovative therapies when conventional options have failed.

Conclusion

The interview highlights CytoMed's unique "low-cost survival strategy" within the highly expensive biotechnology sector.

By leveraging:

* Southeast Asia's lower manufacturing and labour costs
* Strategic hospital partnerships
* China's "Directive 818" policy framework

the company has identified a pragmatic commercialization pathway during the ongoing biotech capital winter.

CytoMed's approach demonstrates not only technological ambition, but also strong strategic insight into the evolving global biotechnology landscape.

Media Contact
Company Name: CytoMed Therapeutics Ltd
Contact Person: Ms Evelyn
Email: Send Email [http://www.universalpressrelease.com/?pr=cytomed-therapeutics-ltd-nasdaq-gdtc-a-rising-star-in-singapores-cancer-biotechnology-sector]
Country: Singapore
Website: https://www.cytomed.sg/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.